- Company
- Qsimia's sales exceeded ₩200 billion
- by An, Kyung-Jin Apr 9, 2021 05:55am
- Alvogen Korea surpassed &8361;200 billion in annual sales for the first time since its launch in Korea. Qsymia, an obesity treatment drug released at the beginning of last year, and the obesity treatment Qsymia, which was released earlier last year, produced the largest sales. According to the Financial Supervisory Service on the 7th, Alvoge
- Company
- Betadine, disposes of 3 months of advertising suspension
- by Nho, Byung Chul Apr 8, 2021 05:55am
- Mundipharma's Betadine Throat Spray (Povidone Iodine) was suspended from advertising by the MFDS. Mundipharma recently sent a notice regarding administrative disposition to pharmacies that handle the product, and requested cooperation in the removal of Betadine advertising installations in pharmacies. The advertisement business suspension
- Policy
- Review underway for nation's first DPP-4+SGLT-2 inhibitor
- by Lee, Tak-Sun Apr 8, 2021 05:55am
- Domestic companies are one step closer to commercializing DPP-4 inhibitor and SGLT-2 inhibitor combination therapies in Korea. Until now, there were only imported DPP-4+SGLT-2 inhibitor combination therapies available, but Korean pharmaceutical companies have now started to target the market with new developments. According to indust
- Policy
- Novo applies for approval of the first oral GLP-1 treatment
- by Lee, Tak-Sun Apr 8, 2021 05:55am
- An oral tablet formulation of the GLP-1 receptor agonist diabetes treatment that was previously only available as an injection is preparing to launch in Korea. The drug is Novo Nordisk’s ‘Rybelsus (semaglutide).' Novo Nordisk has recently applied for the approval of its Rybelsus tablet to the Korean Ministry of Food and Drug Safety (MF
- Company
- Zytiga listed as a prostate cancer selective benefit
- by Apr 8, 2021 05:55am
- Janssen announced on the 7th that it will be applied as a first-line treatment for patients with high-risk metastatic prostate cancer with hormone-responsiveness from the 1st. Zytiga, as a CYP17 inhibitor, was approved by the MFDS in July 2012 as a treatment for metastatic castration-resistant prostate cancer, and added hormone-responsive
- Company
- One-on-one briefing sessions with doctors are not allowed
- by Apr 8, 2021 05:55am
- It is expected that MSD Korea will in principle ban one-on-one product presentations for individual doctors from May. Business restrictions are much stronger than the industry's 'fair competition rules'. According to the pharmaceutical industry on the 7th, MSD Korea announced plans to improve CP to its employees on the 5th. From May, it w
- Policy
- The NHIS sequentially began managing the entire drug cycle
- by Lee, Hye-Kyung Apr 8, 2021 05:54am
- The NHIS prepares management measures such as treatment effect and cost effectiveness after registration. The NHIS sequentially began managing the entire drug cycle. The NHIS began recruiting external researchers to prepare post-evaluation plans based on actual clinical data after listing drugs exempted from PE Study. This research service is
- Company
- Tumor-agnostic ‘Rozlytrek’ seeks PE exemption
- by Eo, Yun-Ho Apr 7, 2021 06:03am
- Discussions will begin for the listing of Roche's anticancer drug ‘Rozlytrek,’ which may be prescribed regardless of cancer type if specific conditions are met. According to industry sources, 2 types of anticancer drugs by Roche Korea &8211; Rozlytrek (entrectinib) and Polivy (polatuzumba) &8211; will be up for deliberation by the
- Company
- Beovu heats up the AMD treatment market with its ease of use
- by Apr 7, 2021 06:01am
- Novartis has jumped into the competition in the macular degeneration treatment market with ‘Beovu.’ Emphasizing its longer treatment interval, the new drug is fiercely chasing the market leader ‘Eylea.’ Beovu (brolucizumab) is a treatment for wet (neovascular) age-related macular degeneration (AMD) launched by Novartis as a successo
- Policy
- 1.25 million doses of Pfizer vaccine were released
- by Lee, Tak-Sun Apr 7, 2021 06:01am
- It was found that 1.25 million doses of Pfizer vaccine, which had been individually contracted so far, received lot release from the MFDS. Following 1 million doses arriving in March, an additional 250,000 doses received lot release from the government in April, and vaccinations started to the general public. According to the MFDS on
